Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
- Conditions
- Retinal Vein Occlusion
- Registration Number
- NCT01875770
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.
- Detailed Description
People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 47
- All patients who have been enrolled in the following three trials will be included in the study:
A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean change from baseline in BCVA at 5 and 10 years. 10 years Mean change from baseline in BCVA at 5 and 10 years.
- Secondary Outcome Measures
Name Time Method Mean change from baseline in foveal thickness at 5 and 10 years 10 years Mean change from baseline in foveal thickness at 5 and 10 years
Trial Locations
- Locations (1)
Wilmer Eye Institute
🇺🇸Baltimore, Maryland, United States